Other important applications for beta-blockers in high-risk patients.

Brent M. Egan, Robert J Chilton

Research output: Contribution to journalArticle

Abstract

Beta-blockers suppress the adverse effects of chronic activation of the sympathetic nervous system-which plays an important role in the progression of cardiovascular disease- and the drugs are also recommended as primary therapy in other diverse medical conditions that present treatment problems. For many patients with atrial fibrillation, a common condition that poses a high risk of stroke, heart rate control with beta-blockers is increasingly seen as a critical therapeutic component. Similarly, perioperative beta-blocker use provides clinical benefits in patients undergoing noncardiac surgery who are at risk of cardiac events. In migraine therapy, beta-blockers are well established as effective agents for prophylaxis, and beta-blockers may reduce levels of C-reactive protein, a sensitive marker of inflammation in cardiovascular disease. Reviewing the role of beta-blockers in several ancillary conditions should help illuminate various aspects of the complex progression of cardiovascular disease and clarify the drugs' various therapeutic benefits.

Original languageEnglish (US)
Pages (from-to)35-48
Number of pages14
JournalPostgraduate Medicine
Volume114
Issue number6 Suppl Role
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Cardiovascular Diseases
Therapeutics
Cardiovascular Agents
Sympathetic Nervous System
Migraine Disorders
C-Reactive Protein
Atrial Fibrillation
Heart Rate
Stroke
Inflammation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Egan, B. M., & Chilton, R. J. (2003). Other important applications for beta-blockers in high-risk patients. Postgraduate Medicine, 114(6 Suppl Role), 35-48.

Other important applications for beta-blockers in high-risk patients. / Egan, Brent M.; Chilton, Robert J.

In: Postgraduate Medicine, Vol. 114, No. 6 Suppl Role, 12.2003, p. 35-48.

Research output: Contribution to journalArticle

Egan, BM & Chilton, RJ 2003, 'Other important applications for beta-blockers in high-risk patients.', Postgraduate Medicine, vol. 114, no. 6 Suppl Role, pp. 35-48.
Egan, Brent M. ; Chilton, Robert J. / Other important applications for beta-blockers in high-risk patients. In: Postgraduate Medicine. 2003 ; Vol. 114, No. 6 Suppl Role. pp. 35-48.
@article{340545df66cc43598d031d5ef33c6457,
title = "Other important applications for beta-blockers in high-risk patients.",
abstract = "Beta-blockers suppress the adverse effects of chronic activation of the sympathetic nervous system-which plays an important role in the progression of cardiovascular disease- and the drugs are also recommended as primary therapy in other diverse medical conditions that present treatment problems. For many patients with atrial fibrillation, a common condition that poses a high risk of stroke, heart rate control with beta-blockers is increasingly seen as a critical therapeutic component. Similarly, perioperative beta-blocker use provides clinical benefits in patients undergoing noncardiac surgery who are at risk of cardiac events. In migraine therapy, beta-blockers are well established as effective agents for prophylaxis, and beta-blockers may reduce levels of C-reactive protein, a sensitive marker of inflammation in cardiovascular disease. Reviewing the role of beta-blockers in several ancillary conditions should help illuminate various aspects of the complex progression of cardiovascular disease and clarify the drugs' various therapeutic benefits.",
author = "Egan, {Brent M.} and Chilton, {Robert J}",
year = "2003",
month = "12",
language = "English (US)",
volume = "114",
pages = "35--48",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "6 Suppl Role",

}

TY - JOUR

T1 - Other important applications for beta-blockers in high-risk patients.

AU - Egan, Brent M.

AU - Chilton, Robert J

PY - 2003/12

Y1 - 2003/12

N2 - Beta-blockers suppress the adverse effects of chronic activation of the sympathetic nervous system-which plays an important role in the progression of cardiovascular disease- and the drugs are also recommended as primary therapy in other diverse medical conditions that present treatment problems. For many patients with atrial fibrillation, a common condition that poses a high risk of stroke, heart rate control with beta-blockers is increasingly seen as a critical therapeutic component. Similarly, perioperative beta-blocker use provides clinical benefits in patients undergoing noncardiac surgery who are at risk of cardiac events. In migraine therapy, beta-blockers are well established as effective agents for prophylaxis, and beta-blockers may reduce levels of C-reactive protein, a sensitive marker of inflammation in cardiovascular disease. Reviewing the role of beta-blockers in several ancillary conditions should help illuminate various aspects of the complex progression of cardiovascular disease and clarify the drugs' various therapeutic benefits.

AB - Beta-blockers suppress the adverse effects of chronic activation of the sympathetic nervous system-which plays an important role in the progression of cardiovascular disease- and the drugs are also recommended as primary therapy in other diverse medical conditions that present treatment problems. For many patients with atrial fibrillation, a common condition that poses a high risk of stroke, heart rate control with beta-blockers is increasingly seen as a critical therapeutic component. Similarly, perioperative beta-blocker use provides clinical benefits in patients undergoing noncardiac surgery who are at risk of cardiac events. In migraine therapy, beta-blockers are well established as effective agents for prophylaxis, and beta-blockers may reduce levels of C-reactive protein, a sensitive marker of inflammation in cardiovascular disease. Reviewing the role of beta-blockers in several ancillary conditions should help illuminate various aspects of the complex progression of cardiovascular disease and clarify the drugs' various therapeutic benefits.

UR - http://www.scopus.com/inward/record.url?scp=70349239212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349239212&partnerID=8YFLogxK

M3 - Article

C2 - 19667668

AN - SCOPUS:70349239212

VL - 114

SP - 35

EP - 48

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 6 Suppl Role

ER -